Management of Intrahepatic Cholestasis of Pregnancy: Recommendations of the Working Group on Obstetrics and Prenatal Medicine – Section on Maternal Disorders

Management der intrahepatischen Schwangerschaftscholestase (Intrahepatic Cholestasis of Pregnancy – ICP): Empfehlungen der Arbeitsgemeinschaft Geburtshilfe und Pränatalmedizin (AGG – Sektion Maternale Erkrankungen)

Authors
Carsten Hagenbeck1, Amr Hamza2–3, Sven Kehl4, Holger Maul5, Frank Lammert6, Verena Keitel7, Matthias C. Hütten8, Ulrich Pecks9

Affiliations
1 Universitätsklinikum Düsseldorf, Frauenklinik, Düsseldorf, Germany
2 Universitätsklinikum des Saarlandes, Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Homburg, Germany
3 Kantonsspital Baden AG, Baden, Switzerland
4 Frauenklinik, Friedrich Alexander University Erlangen Nuremberg, Faculty of Medicine, Erlangen, Germany
5 Section of Prenatal Diagnostics and Therapy, Asklepios Klinik Barmbek, Hamburg, Germany
6 Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg, Germany
7 Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany
8 Clinique E2 Neonatology, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands
9 Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany

Key words
stillbirth, induction of labour, bile acids, liver disease, ursodeoxycholic acid, pruritus

Schlüsselwörter
Totgeburt, Weheneinleitung, Gallensäuren, Lebererkrankung, Ursodeoxycholsäure, Pruritus

received 13.1.2021
accepted after revision 5.2.2021

Bibliography
Geburtsh Frauenheilk 2021; 81: 922–939
DOI 10.1055/a-1386-3912
ISSN 0016-5751
© 2021. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Correspondence
Dr. Carsten Hagenbeck
Universitätsklinikum Düsseldorf Frauenklinik
Moorenstraße 5, 40225 Düsseldorf, Germany
Carsten.Hagenbeck@med.uni-duesseldorf.de

Deutsche Version unter:
https://doi.org/10.1055/a-1386-3912

ABSTRACT
Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease specific to pregnancy. The cardinal symptom of pruritus and a concomitant elevated level of bile acids in the serum and/or alanine aminotransferase (ALT) are suggestive for the diagnosis. Overall, the maternal prognosis is good. The fetal outcome depends on the bile acid level. ICP is associated with increased risks for adverse perinatal outcomes, including preterm delivery, meconium-stained amniotic fluid, and stillbirth. Acute fetal asphyxia and not chronic uteroplacental dysfunction leads to stillbirth. Therefore, predictive fetal monitoring is not possible. While medication with ursodeoxycholic acid (UDCA) improves pruritus, it has not been shown to affect fetal outcome. The indication for induction of
Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease in pregnancy. Its prevalence in Western Europe is 0.3% to 0.7%. ICP is an interdisciplinary challenge as it is associated with serious perinatal complications such as prematurity; meconium stained amniotic fluid; neonatal adaptation syndrome; and even intrauterine fetal death. There are no uniform international recommendations. On the contrary, algorithms for pregnancy management vary considerably between international guidelines. There are no national recommendations.

This paper aims to summarise the current literature on intrahepatic cholestasis of pregnancy into structured background information and to provide interdisciplinary consensus-based recommendations based on the available evidence.

**Method**

In preparation for the present recommendations, a systematic literature search in PubMed and Web of Science was undertaken in October 2020. The database search was performed without time limitation using the search terms “intrahepatic cholestasis of pregnancy”, “obstetric cholestasis”, “intrahepatic cholestasis in pregnancy” and “pregnancy cholestasis” as “OR” links and after exclusion of duplicates yielded 1379 publications. Based on the literature, the statements in the existing guidelines of various multidisciplinary medical societies were reviewed according to the latest evidence-based research. The structure was revised and primarily follows a pragmatic sequence for clinical application while considering didactic aspects. To this end, the criteria of currentness and relevance for clinical management of ICP identified 219 articles from the search output above. After completion of the full text review, 126 publications were considered for the compilation of the present recommendation. Significant sources from the associated disciplines of hepatology/gastroenterology and neonatology as well as pharmacological product characteristics complemented this review. The guideline #53 “Intrahepatic Cholestasis of Pregnancy” published by the Society for Maternal-Fetal Medicine (SMFM) in November 2020 and the study protocol of the TURRIFIC study (published on 12 January 2021) were included later on. Thus, this paper includes a total of 161 sources.

**Definition**

Intrahepatic cholestasis of pregnancy is characterised by a pathological elevation of hepatobiliary retention parameters in maternal blood in pregnancy. Clinical signs are pruritus without skin rash in combination with elevated bile acid and/or transaminase levels in the blood. Complications in ICP are mainly associated with elevated bile acid levels, which is why the bile acid level should be assayed. In case of bile acid levels > 10 µmol/L (fasting) or > 14 µmol/L (postprandial), ICP is likely. Usually spontaneous remission after birth can be expected. ICP is a diagnosis of exclusion.
STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
Intrahepatic cholestasis of pregnancy (ICP) is present in bile acid levels > 10 µmol/L (fasting) or > 14 µmol/L (postprandial). The diagnosis of ICP may also be raised if bile acid levels are unremarkable and the patient has both pruritus and elevated transaminase levels.

Epidemiology
ICP is the most common pregnancy-related disease of the liver [1]. Due to ethnicity, its prevalence varies greatly between geographical regions and is significantly higher in Latin American than Caucasian women [2]. The prevalence of ICP is estimated at 0.1% to 15% of all pregnancies worldwide [3,4], even reaching 22% in certain populations in Chile (Araucanian Indians) [5]. The robustness of this data, most of which is over 50 years old, is questionable on the grounds of inconsistent definitions. A recent multi-ethnic study from Australia found an overall prevalence of 0.7%. High prevalence is seen in pregnant Asian (especially from India and Pakistan) and indigenous women [6,7]. In Sweden, a population-based analysis of 1,213,668 singleton pregnancies in the Swedish Birth Registry from 1997 to 2009 reported an incidence of 0.32% to 0.58% [8]. Similar data is described for Finland (0.4%) [9]. There is no accurate data on the incidence in Germany.

Aetiology and Pathogenesis
ICP is multifactorial and not fully understood. A combination of genetic disposition, hormonal and environmental factors appears to favour its onset [10–13]. It is caused by impaired hepatobiliary transport resulting in retention of substances physiologically excreted with bile. Membrane-bound transport systems of hepatocytes are responsible for the elimination of bile acids and other toxic substances. The processes take place via ATP-binding cassette transporters (ABC), whose expression is regulated via transcription factors, such as FXR and SXR/PXR [14–16]. These transport processes may be affected by various mechanisms [17–20]:
1. Genetic mutations alter the expression or function of membrane-bound transporters such as ABCB4, ABCB11 and ATP8B1.
2. Endogenous and exogenous substances, such as steroid hormones and medication (cetirizine, methyldopa, macrolide antibiotics, etc.), can interfere with transcription factors regulating the activity of the hepatobiliary transport system [14–16, 21–24].
3. One result of the reduced excretion is the accumulation of toxic substances, which has a negative impact on the function and expression of transport proteins [25].

The retention of hepatobiliary substances such as bile acids and progesterone sulphates leads to elevated blood levels with accumulation in organs resulting in cytotoxic and hormone-mediated organ dysfunction.

The primary bile acids are conjugated with glycine and taurine and secreted into the duodenum. Glycine-conjugates predominate in unremarkable pregnancies, whereas in ICP the blood levels of toxic taurine-conjugates are elevated [26]. In the in vitro animal model, taurine-conjugates have an irreversible negative effect on the rhythm and contraction amplitude of neonatal cardiomyocytes [27].

Risk Factors
Table 1 lists the risk factors for ICP development. Genetic mutation variants (see above) and previous or concomitant hepatobiliary disease [28–30] in particular, as well as elevated maternal oestrogen levels, favour the development of ICP [22].

High oestrogen levels in multiple pregnancies [31] as well as in early pregnancy after ovarian hyperstimulation [32,33] are independent risk factors. The prevalence in large population twin pregnancies has been reported at 6.2–8.7% [6,34,35], in analyses of small case numbers up to 22% [31]. Changes in progesterone metabolism leading to large amounts of sulphated progesterone metabolites may also contribute to saturation of hepatocellular

| Table 1 | Risk factors in ICP. |
| Contributory factor | Risk |
| Genetic predisposition: particularly: ABCB4, ABCB11, ATP8B1, ABCC2, NR1H4, TJP2 | unclear, effect more likely strong [41,42] |
| Liver disease: | |
| ▪ Hepatitis C | OR 20.40 (95% CI 9.39–44.33) [28] |
| ▪ Hepatitis B | OR 1.68 (95% CI 1.43–1.97) [29] |
| ▪ Cholelithiasis | OR 3.29 (95% CI 2.02–5.36) [30] |
| Multiple pregnancy (prevalence) | 6–9% [6,34,35] |
| Elevated oestrogen/ progesterone levels | unclear |
| Stimulation in assisted reproductive technology (ART) | RR 3.8 (95% CI 1.0–15.0) [43] |
| Nutritional deficits | Vitamin D [44] |
| Environmental factors | Selenium [45] |
| ICP in previous pregnancy (risk of recurrence) | 45–70% [47] |
Maternal risks

Maternal prognosis during pregnancy is favourable. The mainly nocturnal pruritus can be quite distressing, even agonising. The resulting mental stress can be exacerbated by insomnia and fatigue. However, the severity of the pruritus does not correlate with the maternal bile acid serum level [48,49].

In addition, the course of pregnancy can be affected by comorbidities such as diabetes mellitus/gestational diabetes and arterial hypertension/pre-eclampsia [8]. Compared to pregnancies without ICP, the incidence of gestational diabetes is higher (13.6% vs. 8.5%, OR 1.68; 95% CI 1.04–2.72, p < 0.03), as is the incidence of pre-eclampsia (7.78% vs. 2.41%, OR 3.74; 95% CI 1.04–12.0, p < 0.03) [50]. The probability of pre-eclampsia increases the earlier ICP manifests in pregnancy. The time lag is about 2–4 weeks, with proteinuria usually preceding hypertension [53]. The coincident presence of acute fatty liver in pregnancy has been described, but without proven causality [54]. Prolonged prothrombin time may be secondary to ICP-induced steatorrhoea and the use of bile acid complexing agents (e.g., colestyramine) [55] with subsequent vitamin K deficiency, thus increasing the peripartum bleeding risk [56–58]. In an ICP cohort of 348 pregnant women treated solely with UDCA, postpartum blood loss did not differ from the normal population [59].

An increased rate of cardiac arrhythmias has been described, the cause of which is a direct arrhythmogenic effect of bile acids on adult cardiomyocytes [60–63]. This observation has no clinical consequence.

In the long term, patients who have experienced ICP are at increased risk of developing various liver; biliary; pancreatic; metabolic; and immune-mediated diseases (see section on “Postpartum care and follow-up”) [10,30,64,65].

Fetal and neonatal risks in ICP

Bile acids accumulate in the placenta, fetus and amniotic fluid [3,66]. They can thus harmfully affect the fetus.

Stillbirth – intrauterine fetal demise (IUFD)

Stillbirth is the most feared complication of ICP. For singleton pregnancies, the prevalence is 0.83% compared to 0.32–0.44% in healthy pregnant women [67,68]. Currently, there are no predictive markers linked to the event of IUFD. The aetiology is poorly understood. It is argued that fetal peak bile acid levels are crucial and that toxic levels of taurine-conjugates induce fetal arrhythmias and vasoconstriction of the chorionic veins [69–71]. Even if placental morphology is altered [72,73], intrauterine death is an acute event.

The level of the bile acid concentration affects the risk for the onset of stillbirth. Common clusters for risk determination are levels up to 40 µmol/L, 40–99 µmol/L and ≥ 100 µmol/L [74–78]. In a recent meta-analysis of individual patient data by Ovadia et al. of 4936 women with ICP, the IUFD rate increased significantly after gestational week 34 when a bile acid level ≥ 100 µmol/L was exceeded. The prevalence in singleton pregnancies was 3 in 2310 women with serum bile acid levels < 40 µmol/L (0.13%; 95% CI 0.02–0.38), 4 in 1412 women (0.28%; 0.08–0.72) with levels of 40–99 µmol/L (HR 2.35; 95% CI 0.52–10.50; p = 0.26) and 18 (3.44%; 2.05–5.37) in 524 women with levels ≥ 100 µmol/L (HR 30.50; 8.83–105.30; p < 0.0001) [68].

There is an association between bile acid level, gestational age and occurrence of stillbirth.
Preterm birth

Increased rates of indicated and spontaneous preterm birth have been described in women with ICP [3,8,56,57,74,79–84]. In studies the iatrogenic preterm birth resulting from a physician’s decision to deliver is consistently and significantly increased [56, 57,68,76,81–83]. Of equal clinical importance is spontaneous preterm birth: the meta-analysis by Ovadia et al. showed an increased risk of almost 3.5-fold (OR 3.47 [95% CI 3.06–3.95]). According to them, the risk increases with the bile acid level and particularly so at levels above 100 µmol/L (≥100 µmol/L vs. <40 µmol/L): HR 2.77 (95% CI 2.13–3.61; p < 0.0001); 40–99 µmol/L vs. <40 µmol/L: HR 1.34 (95% CI 1.06–1.69; p = 0.0158). The population-based Swedish cohort study of more than 1.2 million singleton pregnancies by Wikström Shemer et al. found an increased rate of late preterm births among women with ICP (32 + 0 to 37 + 0; aOR 3.30, 95% CI 3.00–3.63), but fewer preterm births before gestational week 32 + 0 (aOR 0.47, 95% CI 0.27–0.81) [8].

Neonatal complications

The risk of the neonate being admitted to a neonatal unit more than doubles with severe maternal cholestasis (12% vs. 5.6%) [34,68]. The most important factor here is prematurity [90]. Regardless, neonatal respiratory distress syndrome was a specific risk of ICP (aOR 2.56; 95% CI 1.26–5.18) [91]. Elevated bile acid levels are thought to affect alveolar enzyme function, resulting in surfactant inactivation and a pulmonary inflammatory response with resultant respiratory distress syndrome [92–94]. The association of ICP with other neonatal complications has only been described in small populations. In a retrospective cohort study in infants of mothers with bile acid levels >100 µmol/L, the retrospective cohort study by Herrera et al. showed a risk, increased by a factor of 5.6 after adjustment for gestational age at delivery, of neonatal morbidity defined as hypoxic ischaemic encephalopathy (HIE), severe intraventricular haemorrhage (IVH, grade 3–4), bronchopulmonary dysplasia (BPD), necrotising enterocolitis (NEC), and postnatal death. However, the total number of events (30 in 785 pregnancies) in this study was small, and no patient developed isolated IVH or HIE [85]. In contrast, Kawakita et al. in a retrospective multicentre cohort study of 233 women after adjustment (age; ethnicity; hypertension; diabetes; BMI; duration of pregnancy; bile acid level; intrahepatic cholestasis of pregnancy; use of UDCA; transaminase level; and pre-existing liver disease) could not demonstrate significant neonatal morbidity [76].

Meconium stained amniotic fluid

Meconium stained amniotic fluid at birth is about 4 to 7 times more common in ICP than in women without ICP [83,85] and depends on the bile acid level. Lee et al. found that in women with bile acid levels >20 µmol/L each 10 µmol/L increase resulted in a 19.7% increase in meconium stained amniotic fluid [86]. In levels of >40 µmol/L, Glantz et al. observed meconium stained amniotic fluid in 44% of cases [74]. According to two recent studies, the risk increases by a factor of 1.6–3.5 for bile acid levels between 40 and 100 µmol/L, and by a factor of 3.7–4.6 for levels above 100 µmol/L [76,85]. A rare but serious complication in meconium stained amniotic fluid is fetal meconium aspiration [87]. The incidence of meconium aspiration syndrome in meconium stained amniotic fluid reportedly is up to 5% [87]. It is characterised by early postnatal onset of severe respiratory distress syndrome with subsequent hypoxia. However, the onset of symptoms can also be delayed. Up to one third of neonates with meconium aspiration require intubation with mechanical ventilation to ensure oxygenation [88]. Routine intrapartum aspiration of meconium stained amniotic fluid is not recommended [89].

Symptoms and Time of Manifestation

Pruritus is the hallmark symptom of ICP, and in many cases the only symptom reported. Initially, this typically affects the palms of the hands and soles of the feet. Sometimes the symptoms undergo secondary generalisation. The subjective spectrum of intensity is described as ranging from “mild” to “unbearable”, markedly intensified at night [95]. In up to 80% of cases, ICP manifests after the 30th week of gestation; the time of manifestation is usually in the late 2nd and early 3rd trimester [47,82]. Transitory symptoms in the first trimester are associated with ovarian hyper-
stabilisation syndrome following in vitro fertilisation [32], while persistent and worsening symptoms are characteristic of naturally conceived pregnancies [96]. While localised and generalised pruritus is a common symptom in pregnancy, in up to 9% of cases it is ICP [47,97,98]. However, in more than 80% of cases, ICP manifests as pruritus [34,56]. Although bile acid deposits in the skin are blamed for pruritus, its severity does not correlate with serum bile acid level [48,49]. There are no characteristic skin changes. Scratching may cause secondary efflorescence (dermatographica artefacta), which must be differentiated from other pregnancy dermatoses. These include atopic eruption of pregnancy (AEP), polymorphic eruption of pregnancy (PEP; previously known as PUPP: pruritic urticarial papules and plaques of pregnancy) and gestational pemphigoid (syn.: pemphigus gravidarum, gestational herpes) [99,100]. Accompanying symptoms may include pain in the upper abdomen, nausea, loss of appetite, sleep deprivation, and steatorrhoea. Icterus as an accompanying symptom is quite rare and then occurs with a time lag of about 1 to 4 weeks after the initial pruritus. Some regional data put the incidence of jaundice as high as 25% [74,100–103]. Symptoms of icterus, such as dark urine and light to greyish stools, should be assessed by differential diagnosis.

Diagnosis

ICP is a diagnosis by exclusion. The cardinal symptom pruritus is suggestive and should prompt further workup [104]. The medical history must include a family history and physical examination. In unclear cases, especially in the case of primary skin eruptions, dermatological consultation should be obtained. Clinical chemistry panels can further confirm the suspected diagnosis [57]. It is recommended that the patient be seen by an internist to undergo liver ultrasonography to rule out other cholestatic disease. Table 2 gives an overview of the diseases to be included in the differential diagnosis.

**Laboratory evaluation**

**Bile acids**

Bile acids are synthesised from cholesterol in the liver. First, the primary bile acids (chenodeoxycholic acid and cholic acid) are conjugated with glycine or taurine and secreted into the duodenum. In the intestine, the primary bile acids are transformed into secondary or tertiary bile acids mainly through the action of bacterial enzymes. These are absorbed in the terminal ileum and are thus subject to the enterohepatic circulation. The bile acids detected in the blood originate from intestinal reabsorption.

Various assay techniques are used in bile acid measurement. Total serum bile acids (TBA) and bile acid fractions can be assayed by mass spectrometry and liquid chromatography, which is typically performed in specialised laboratories. Total serum bile acids can also be quantified by an enzymatic assay. This assay is also performed in some hospital laboratories. The enzymatic assay does not detect bile acid fractions individually. Accordingly, medication with the tertiary bile acid ursodeoxycholic acid can result in levels that are falsely high.

The reference values of the different assay techniques are based on fasting samples (according to most manufacturers fasting > 12 h). However, postprandial assaying is possible. Numerous studies show that the postprandial elevation in bile acid levels is only minor [105,106]. If postprandial levels ≥ 100 µmol/L are reached in some cases (without UDCA administration – depending on the type of assay [see above]), follow-up testing can also measure the fasting level for differential diagnostic consideration.

Fasting healthy pregnant women have a normal bile acid level of 6–10 µmol/L and a postprandial level of 10–14 µmol/L. The meta-analysis by Ovadia et al. of fasting pregnant women with ICP (n = 1726) showed a median level of 23.0 µmol/L (IQR 14.7–41) versus 32.0 µmol/L (IQR 19.0–61.5) in postprandial patients (n = 2795) [68]. Irrespective of fasting and UDCA therapy, various analyses have shown the elevated total serum bile acid level to be a sensitive and specific marker (OR = 4.17, p = 0.0037, AUC = 0.62, p = 0.046) in the diagnosis of ICP and the related adverse perinatal outcome [107,108].

Furthermore, normal bile acid levels in pruritus do not rule out the diagnosis of ICP, as it can sometimes take weeks for laboratory changes to manifest [3,56,79,109,110]. Follow-up testing is indicated in these cases if unexplained pruritus persists, and bile acid levels should always be considered in the context of the overall clinical presentation.

**STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE**

- In fasting blood, the upper reference range of bile acid levels is 6–10 µmol/L and in postprandial blood 10–14 µmol/L.
- Sometimes it may take up to four weeks after the initial pruritus for laboratory results to become abnormal.
- Normal bile acid levels in pruritus do not rule out the diagnosis of ICP.
- Ursodeoxycholic acid medication may yield falsely high values, depending on the assay technique employed.

**Transaminases**

When pruritus is present in ICP, 60% of patients can be expected to develop elevated AST/ALT levels two to thirty times above normal. The elevation in transaminase levels does not correlate with bile acid levels [111–113]. ALT activity is independent of pregnancy and together with corresponding clinical signs can firm up the diagnosis even if there is no bile acid elevation [109,112].
| Differential diagnoses in ICP [99, 100, 116 – 118]. |
|---------------------------------------------------------------|
| **Differential diagnoses** | **Clinical presentation** | **Time of manifestation** | **Features differentiating it from ICP** |
| Pruritus in pregnancy | | | |
| Pruritus gravidarum | Pruritus (generalised) | mostly 3rd trimester | as ICP, no change in laboratory values (AST/ALT, TBA) |
| Atopic eruption of pregnancy (AEP) | Pruritus, extensive eczema- tous papules on the flexor aspect (70%) or disseminated papules and prurigo lesions on the extensor aspect (30%) | 75% before 3rd trimester | no changes in clinical chemistry (AST/ALT, TBA), typical skin rashes |
| Gestational pemphigoid (syn.: pemphigus gravidarum, gestational herpes) | Pruritus days to weeks before vesicular exanthema. Plump periumbilical bullae on pruritic urticarial erythema. | Onset in the 3rd trimester, postpartum | Typical skin efflorescences, complement-binding autoantibodies also bind to basement membrane of the chorionic and amniotic epithelium (→ SGA, IUGR). Diagnosis confirmed by immunofluorescence. Lab panel: Eosinophilia, AST/ALT, TBA not elevated. |
| Polymorphic eruption of pregnancy (PEP, formerly: PUPP) | Pruritus – frequent onset in the striae distensae. Exanthema (nodules, plaques) on the abdomen (periumbilical sparing), thighs, buttocks, arms, and lateral aspects of the trunk. | last weeks of pregnancy or immediately postpartum (15%) | no changes in clinical chemistry (AST/ALT, TBA), typical skin rashes |
| Pre-existing causes of pruritus | | | |
| Atopic dermatitis | Pruritus | entire pregnancy | Medical history, neurodermatitis |
| Allergic skin reactions | Pruritus | entire pregnancy | Medical history |
| Clinical conditions with liver dysfunction specific to pregnancy | | | |
| HELLP syndrome | Pain upper quadrants, hypertension, headache, neurological deficits | 2. + 3rd trimester and postpartum | Pain upper quadrants, haemolysis, neurological deficits. Lab panel: Haptoglobin ↓, AST/ALT ↑, thrombocytopenia, proteinuria |
| Acute fatty liver of pregnancy | General feeling of malaise, polydipsia, polyuria, icterus, nausea, vomiting | 2. + 3rd trimester and postpartum | Hypoglycaemia, leukocytosis, hyperbilirubinaemia, antithrombin ↓, prothrombin time ↑, (creatinine ↑) |
| Hyperemesis gravidarum | Nausea, vomiting | mainly 1st trimester | Usually limited to 1st trimester, AST/ALT ↑ – rapidly normal after cessation of symptoms, ketonuria, ketonaemia |
| Other liver dysfunctions | | | |
| Viral hepatitis (A, B, C, D, E) | Icterus, nausea, vomiting, abdominal pain | entire pregnancy | General symptoms, antibodies in the blood |
| Primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC) | Pruritus, icterus, nausea, lethargy, fatigue, performance slump | Symptoms before pregnancy | Liver ultrasonography, MRCP. Antibodies: PSC: pANCA PBC: AMA |
| Autoimmune hepatitis | Icterus, fatigue, nausea, loss of appetite | Symptoms before pregnancy | Antibody constellation: ANA, SMA, SLA |
| Bile duct obstruction (e.g. cholelithiasis) | abdominal pain | entire pregnancy | Liver ultrasonography, MRI |
| Medication, drugs | Pruritus, icterus | at any time | Medical history, timing of application/abuse and symptoms |

Acronyms: PEP – Polymorphic eruption of pregnancy, PUPP – pruritic urticarial papules and plaques of pregnancy, MRCP – Magnetic resonance cholangio-pancreatography, SMA – smooth muscle antibody, SLA – soluble liver antigen, pANCA – perinuclear staining pattern of anti-neutrophil cytoplasmatic antibodies, AMA – anti-mitochondrial antibody, ANA – anti-nuclear antibody, AST – aspartate transaminase, ALT – alanine transaminase, TBA – total bile acids.
Hemostasis
ICP does not affect coagulation. In case of pre-existing vitamin K deficiency in the context of steatorrhoea or the administration of bile acid complexing agents (e.g., colestyramine), prothrombin time may be prolonged. This is caused by a decrease in vitamin K-dependent factors (II, VII, IX or X) and thus there is an increased risk of peripartum haemorrhage [56 – 58].

Other laboratory parameters
Elevated direct bilirubin levels are present in up to 20% of cases [57]. Serum gamma GT activity is normal or only moderately elevated, which may be helpful in differential diagnosis. Familial gene mutations, e.g., ABCB4 (MDR3), associated with ICP may present with elevated levels [3, 113, 114]. Due to placental isoenzyme expression with resulting elevated levels, alkaline phosphatase does not play a role in the diagnostic workup of ICP.

Ultrasoundography of the liver
Ultrasound imaging of the liver helps in the differential diagnosis (see section on “Differential diagnoses”). There are no specific findings typical of ICP, the bile ducts are unremarkable [115].

Table 3 Differential diagnosis of liver disease in pregnancy (from [119]).

| Criteria             | HELLP   | Acute fatty liver of pregnancy | Acute viral hepatitis | ICP |
|----------------------|---------|-------------------------------|-----------------------|-----|
| Haemolysis           | ++      | (+)                           | –                     | –   |
| Transaminases ↑      | ++      | ++                            | +++                   | +   |
| Thrombocytopenia     | ++      | secondary +                   | –                     | –   |
| Hypertension         | ++      | 85–95%                        | +                     | 30–50% | –   |
| Proteinuria          | +++     | +                             | –                     | –   |
| Leukocytosis         | –       | +++                            | +                     | –   |
| Kidney failure       | + → +++ | secondary +                   | –                     | –   |
| Neurological symptoms| + → +++ | +                             | –                     | –   |
| Icterus              | (+)     |                               | +                     | +++ (+) |
| Other                | DIC     | Hypoglycaemia                  | Bilirubin ↑           | Pruritus |

RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
The diagnosis of ICP should be confirmed by determining the following laboratory parameters: bile acids, transaminases, gamma GT, total bilirubin, and prothrombin time.

RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
Differential diagnosis should include abdominal ultrasoundography, particularly to rule out the possibility of obstructive cholestasis.

Differential diagnoses
Table 2 provides an overview of the various differential diagnoses in ICP, considering the clinical presentation, time of manifestation and their specific characteristics. Table 3 compares the various manifestations of different parameters in liver disease during pregnancy.

Management of Intrahepatic Cholestasis
Currently, there are no uniform international recommendations for monitoring pregnant women with ICP. Depending on symptom severity, bile acid level and the subjective stress situation of the pregnant woman, both she and her physician should agree on a common goal for the treatment. This also includes setting the timing of delivery against the backdrop of the risk situation, which may have to be readjusted during the pregnancy.

Monitoring the pregnancy
It is unclear how and how often monitoring makes sense, and this is the subject of discussion. Sometimes the laboratory changes only develop with delay. Therefore, follow-up can be useful. If the clinical symptoms are dynamic and TBA ≥ 100 µmol/L, ALT and/or AST > 200 IU/L, laboratory evaluations (bile acids; ALT; AST; gamma GT; bilirubin; and prothrombin time) should be performed more often and, if necessary, inpatient monitoring should be considered. There are no evidence-based follow-up intervals – serial check-ups (e.g., weekly) are not recommended [120].

Rapid, excessive increase or normalisation of the liver enzymes should prompt questioning of the diagnosis of ICP and assessment of possible differential diagnoses.
Bile acid levels $\geq 100 \mu mol/L$ are relevant for treatment (see section on "Delivery timing"). It is unclear whether clinical consequences should also be considered if the levels were initially above the cut-off limits but then were lowered, e.g., with medication. Based on the theory that peak bile acid levels affect outcome, this should be considered when timing the delivery.

The laboratory-specific assay technique is significant when measuring bile acid levels (see section on "Bile acids"). To reduce inaccuracy, UDCA should only be administered after blood has been drawn.

**STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PERNATAL MEDICINE**

It is unclear how and how often pregnant women should be monitored.

**RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PERNATAL MEDICINE**

Follow-up blood chemistry allows an assessment of the following parameter dynamics: bile acids; ALT; AST; gamma GT; total bilirubin; and prothrombin time. The testing intervals depend on the symptoms of each patient.

**Fetal monitoring**

Neither CTG nor Doppler ultrasonography can predict the timing of a possible ICP-specific complication [121]. Therefore, antenatal monitoring is controversial. While CTG changes in ICP have been reported, they are not associated with intrauterine fetal death [38]. Stillbirth in ICP is a sudden event without evidence of placental dysfunction. There is no association with either fetal growth restriction or oligohydramnios [3, 82, 84, 109]. Other fetal monitoring techniques, such as amniocentesis and transcervical amniocentesis, fetal electrocardiography, fetal echocardiography, and fetal movement pattern monitoring are not adequate for ICP monitoring. There is no association with either fetal growth restriction or oligohydramnios [3, 82, 84, 109]. Other fetal monitoring techniques, such as amniocentesis and transcervical amniocentesis, fetal electrocardiography, fetal echocardiography, and fetal movement pattern monitoring are not adequate for ICP monitoring.

Even without evident proof of efficacy, regular follow-up is established in clinical routine, mostly by CTG and ultrasonography. Follow-up intervals should be based on pre-existing comorbidities of the mother and the ICP-specific risk profile in TBA $\geq 100 \mu mol/L$. During delivery, continuous fetal monitoring should be performed.

**STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PERNATAL MEDICINE**

Neither ultrasonography/Doppler ultrasound nor cardiocography are able to predict stillbirth in ICP patients. Evidence-based follow-up intervals therefore do not exist.

**Topical agents**

Various creams and ointments are used: For example, 2% water-based menthol cream or dimetindene maleate gel may help relieve the itching. Topical treatment does not affect laboratory parameters or perinatal outcome [126].

**Ursodeoxycholic acid (UDCA)**

UDCA is a naturally occurring bile acid derivative with an antischolestatic effect in the human body. UDCA is commonly used off-label in the treatment of ICP. UDCA has several cholestasis-preventing effects, in particular the induction of hepatic metabolic enzymes and bile acid transporters increases the excretion of bile acids, protects the cholangiocytes of the bile epithelium from the cytotoxicity of bile acids and protects hepatocytes from bile acid-induced apoptosis.

Several prospective randomised trials on the treatment of ICP have been carried out [127 – 131]. The PITCHES trial, published in...
2019, aimed to prevent stillbirths by UDCA medication. 605 pregnant women with ICP were prospectively randomised in double-blind fashion to the study arm UDCA (initial 2 × 500 mg daily) or placebo. The UDCA group demonstrated an improvement in pruritus and ALT levels. Compared to placebo, UDCA treatment did not improve the combined perinatal outcome (neonatal mortality, preterm birth, NICU admission): 23 vs. 27% (RR 0.85; 95% CI 0.62–1.15). However, the total number of stillbirths (n = 3) in the trial was rather small [127]. The strict induction policy of the trial, conducted in England and Wales, from 37 + 0 weeks gestation may have contributed to this [57]. A secondary subgroup analysis could not identify any cohort in whom UDCA significantly reduced TBA levels or pruritus [132]. The analyses did not consider which dose of UDCA each pregnant woman had taken and over which period, which considerably weakens the significance [133]. A Cochrane review published in July 2020 on the use of UDCA in ICP highlights the benefit in reducing pruritus, but not in preventing stillbirth or spontaneous preterm birth [126]. However, there are the following trends in perinatal outcome with UDCA compared to placebo:

- IUFT/stillbirths: RR 0.33 (95% CI 0.08–1.37; 6 trials, n = 955).
- Transfer to NICU: RR 0.77 (95% CI 0.55–1.08; 2 trials, n = 764).
- Spontaneous preterm birth: RR 0.78 (95% CI 0.49–1.23; 3 trials, n = 749).
- Spontaneous and iatrogenic preterm births: RR 0.60 (95% CI 0.37–0.97; 3 trials, n = 819).

In addition to the perinatal effects, long-term effects are also suspected. For example, it has recently been shown that treatment with UDCA has a favourable effect on fetal lipid metabolism [134].

UDCA treatment is safe and has few side effects [127]. The latter are limited to gastrointestinal symptoms ranging from pasty stools to diarrhoea [135]. The initial oral dose usually is 3 × 250 mg or 2 × 500 mg. Dosing may be adjusted depending on the maternal symptoms. The maximum UDCA dose often administered in trials is 2000 mg. In this context it is used off-label. Dose recommendations vary and are mostly 10–15 mg/kg bw [104, 127].

**RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE**

If ICP is suspected clinically, oral treatment with ursodeoxycholic acid should be initiated irrespective of bile acid levels, with the goal of alleviating maternal symptoms.

**Rifampicin**

Rifampicin is a broad-spectrum antibiotic administered in pregnancy to treat tuberculosis [136]. The medication lowers the serum bile acid level in cholestasis outside pregnancy [137]. Experience with ICP treatment is limited to a handful of reports on pregnant women in combined use with UDCA after failed single-agent therapy [138, 139]. The total daily dose of rifampicin was between 300 and 1200 mg. Pruritus improved in 11 out of 16 (69%) patients and bile acid levels decreased in 14 out of 27 (54%). All infants were delivered between 32 and 37 weeks gestation with an unremarkable outcome. The recruiting Australian TURRIFIC-trial (EudraCT number: 2018-004011-44) [140] targets a comparison of rifampicin with UDCA.

**Colestyramine**

As an anion-exchange resin, colestyramine prevents the reabsorption of bile acids in the enterohepatic circulation. The sequela of this malabsorptive treatment is steatorrhoea with excretion of fat-soluble vitamins. Decreased vitamin K levels may result in significant peripartum bleeding complications in mothers and neonates [141]. A trial with 84 pregnant women comparing UDCA with colestyramine revealed that the anion exchange resin was inferior in all outcome parameters (reduction of pruritus, bile acids and AST/ALT) and worse tolerated (29% nausea/vomiting/ diarrhoea vs. 0% adverse events in the UDCA group) [142]. Because of the mechanism of action, combined treatment with UDCA is counter-productive in terms of the pharmacokinetics.

**S-Adenosyl-L-methionine (SAMe)**

SAMe is metabolised in the liver, among other organs, and serves as a methyl group donor in the biosynthesis of phospholipids for the excretion of oestrogen metabolites [143, 144]. In animal models, SAMe has been shown to reduce cholestasis; the exact mechanism of action is unclear [145]. Studies on SAMe in pregnant women with ICP as a single agent or additive with a dosage of...
400–1600 mg per day did not demonstrate clinical superiority to treatment with UDCA alone [131, 146–148].

**RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE**
At this stage, SAMe cannot be recommended in the treatment of ICP.

### Dexamethasone

Three observational studies found improvement in symptoms and laboratory parameters with dexamethasone in the treatment of ICP [149–151]. In a prospective randomised trial comparing oral dexamethasone dosed at 10–12 mg/d with UDCA, no therapeutic benefit was seen [128]. In addition, there are considerable concerns about long-term effects in the child with repeated high doses [152].

**RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE**
Treatment for ICP should not include systemic dexamethasone.

### Antihistamines

The use of antihistamines in ICP has not been tested in clinical trials but appears to provide symptomatic relief of pruritus – the extent to which a sedative side effect has any effect in this regard is unknown [126].

Tremors and diarrhoea have been observed in the neonates with long-term administration of some first-generation H1 antagonists (chlorpheniramine, diphenhydramine, hydroxyzine). These side effects have not yet been reported with the agents clemastine (1st generation) and cetirizine (2nd generation) more commonly administered in Germany [153].

**RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE**
Systemic use of antihistamines in the relief of pruritus may be considered.

### Other treatment approaches

In severe refractory pruritus, endoscopic placement of a nasobiliary tube, MARS (Molecular Adsorbent Recirculating System) therapy or plasmapheresis can provide short-term and effective relief of itching [154]. Due to inadequate studies, there is no evidence of efficacy for other treatment options such as UV light, herbal remedies and phenobarbital.

**STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE**
A bile acid level ≥ 100 µmol/L is a predictive marker for stillbirth and neonatal complications. The time during pregnancy at which the bile acid levels should be determined is not defined.

### Delivery Management

#### Delivery timing

When deciding on the time of delivery, it is important to weigh the risk of IUFT against iatrogenic prematurity with its consequences for the neonate [155, 156]. The bile acid level plays a decisive role as a predictive marker for stillbirth and neonatal complications. In trials its cut-off level ranges from > 40 µmol/L to ≥ 100 µmol/L [68, 74–76]. In the trial with the highest evidence level by Ovadia et al. in 5269 women with ICP, the rate of stillbirth in bile acid levels ≥ 100 µmol/L increases significantly from 34 + 0 weeks of gestation to a prevalence of 3.44%, which is a more than 30-fold increase in the risk compared with the < 40 µmol/L group (HR 30.5; 95% CI 8.83–105.3) (Figs. 2 and 3). In contrast, the risk of stillbirth for bile acid levels of 40–99 µmol/L and < 40 µmol/L does not differ significantly compared to healthy pregnant women and has a prevalence of 0.28% and 0.13%, respectively [67, 68].

Prospective randomised clinical trials on the issue of optimal time of delivery in ICP are lacking. In a retrospective British study, Williamson et al. found 23 (7%) IUFTs among the 352 patients analysed. In singleton pregnancies, IUFTs occurred at a median of 38 + 0 weeks of gestation; in the three Gemini pregnancies before 37 + 0 weeks of gestation [77].

The PITCHES trial compared treatment with UDCA versus placebo and reported three (0.5%) IUFTs among the 604 patients with ICP analysed [127]. Here, the delivery management of the patients followed routine care. Since this trial was conducted in the United Kingdom, it was based on the NICE guideline, which recommends delivery from 37 + 0 weeks of gestation. Thus, the median gestational age at delivery in the PITCHES trial was 38 weeks of gestation, which may have contributed to a reduction in the rate of IUFT. Since in this trial the bile acid levels were only moderately elevated in most patients, this was more of a low-risk ICP population.

**STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE**
A bile acid level ≥ 100 µmol/L is a predictive marker for stillbirth and neonatal complications. The time during pregnancy at which the bile acid levels should be determined is not defined.
Prevalence

0.13% (95% CI 0.03–0.38)

0.28% (95% CI 0.08–0.72)

3.44% (95% CI 2.05–5.37)

Pregnancies

Stillbirths

0–19 20–39 40–59 60–79 80–99

Total bile acids (µmol/L) 100–119 120–139 140–149 ≥ 150

Stillbirth (%)

100 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0

Number of women with ICP

0 200 400 600 800 1000 1200

Stillbirth (%)

Fig. 2 Number of singleton pregnancies with ICP (blue columns) and percentage with IUFT (red columns), by bile acid level. IUFT prevalence by bile acid group (<40 µmol/L, 40–99 µmol/L and ≥ 100 µmol/L) is shown in the graph above (data from [68]).

≥ 100 µmol/L vs. <40 µmol/L:
HR 30.50 (95% CI 8.83–105.30); p < 0.0001

40–99 µmol/L vs. <40 µmol/L:
HR 2.35 (95% CI 0.52–10.50); p = 0.2642

Fig. 3 Kaplan-Meier graph – percentage of foetuses with IUFT between 24 and 40 weeks of gestation in singleton pregnancies with ICP (data from [68]).
STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
The decision to deliver is based on weighing the risk of intrauterine fetal death against iatrogenic preterm morbidity and mortality.

RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
Bile acid levels in maternal blood should be part of the decision-making process regarding the best time of delivery. The time of delivery is determined individually, in a shared decision-making process with the expectant mother.

RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
Analogous to the German AWMF S2k guideline Induction of labour (expert consensus) [157]:
≥ 100 µmol/L:
- induction of labour may be recommended between 34 + 0 and 36 + 6 weeks of gestation.

< 100 µmol/L:
- induction of labour should be recommended at 37 + 0 weeks of gestation.
- induction of labour must be recommended at 38 + 0 weeks of gestation.

Delivery modality
In their retrospective study, Wickström Shemer et al. analysed 25 780 births to determine the risk of emergent caesarean section after active induction management in ICP between 37 + 0 and 39 + 0 weeks of gestation. Of these, 231 women with ICP gave birth during this period. When labour started spontaneously, women with ICP had the same rate of emergent caesarean section (aOR, 1.33; 95% CI 0.60–2.96) and were less likely to undergo emergent caesarean section after induction of labour (aOR, 0.47; 95% CI 0.26–0.86) compared with non-ICP expectant mothers. There was no difference in the risk of fetal asphyxia [158]. Another retrospective case-control study of 64 inductions of labour due to ICP revealed no increased risk of vaginal surgical delivery or caesarean section. Other complication rates, e.g., for postpartum haemorrhage, were comparable to the control group of induced labour without ICP [159].

RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
Choosing the mode of delivery should follow obstetric criteria.

Postpartum Management and Follow-up
The laboratory and clinical changes normalise completely postpartum. In case of persistence beyond a period of 4–8 weeks, the diagnosis of ICP should be questioned.

There is a high rate of recurrence of up to 70% in subsequent pregnancies [47]. Transient recurrent symptoms may also occur in reproductive stimulation treatment; treatment can then take place in the natural or modified natural cycle. In addition, the risk of cholestasis is also increased outside pregnancy. Oestrogen-containing drugs such as contraceptives can cause ICP-like symptoms. With gestagen-only preparations (systemic or IUD), the risk is low [160].

New evidence suggests an increased risk of developing various liver, biliary, pancreatic, metabolic, and immune-mediated disorders. It remains unclear whether pregnancy activates the disease cascade or whether these disorders were already present subclinically before pregnancy [10, 30, 64, 65].

The hazard ratios for subsequent hepatobiliary disease after initial diagnosis of ICP is 2.62 (95% CI 2.47–2.77) with a cumulative annual increase of ~ 1%. In addition, following ICP the risk is highest for the diagnosis of chronic hepatitis (HR 5.96, 95% CI 3.43–10.33), liver fibrosis/cirrhosis (HR 5.11, 95% CI 3.29–10.33), hepatitis C (HR 4.16, 95% CI 3.14–5.51) and cholangitis (HR 4.22, 95% CI 3.13–5.69) [30].

The presence of heterozygous, disease-associated ABCB4 variants favours hepatobiliary sequelae [161]. If genetic testing has detected certain ABCB4 variants, lifelong UDCA administration and annual ultrasound studies (elastography if necessary) and monitoring of laboratory parameters are recommended. Information about the increased incidence of sequelae is mandatory.

STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
The laboratory and clinical changes normalise completely postpartum. Subsequent pregnancies are at elevated risk of recurrence. Outside of pregnancy, the risk of hepatobiliary disorders is increased. Life expectancy is not affected.

STATEMENT BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE
The administration of oestrogen-containing preparations is based on a risk-benefit analysis. Gestagen-only medications are appropriate for contraception after ICP.
RECOMMENDATION BY THE WORKING GROUP ON OBSTETRICS AND PRENATAL MEDICINE

Women with ICP should be informed about the increased risk of developing sequelae. Liver enzymes, especially the transaminases, should be monitored after 6 weeks at the latest. In the case of persistently elevated transaminase levels, the patient should be seen by a hepatologist. More detailed regular follow-up intervals should be scheduled on an individual basis.

Acknowledgements

Many thanks to all who actively participated in this recommendation.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

[1] Sasamori Y, Tanaka A, Ayabe T. Liver disease in pregnancy. Hepatol Res 2020; 50: 1015–1023. doi:10.1111/hepr.13540
[2] Lee RH, Goodwin TM, Greenspoon J et al. The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J Perinatol 2006; 26: 527–532. doi:10.1038/jjp.7211545
[3] Bacq Y, Sapey T, Brechot MC et al. Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology 1997; 26: 358–364. doi:10.1002/hep.510260216
[4] Bacq Y. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 1999; 3: 1–13
[5] Reyes H, Gonzalez MC, Ribalta J et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med 1978; 88: 487–493. doi:10.7326/0003-4819-88-4-487
[6] Gardiner FW, McCuaig R, Arthur C et al. The prevalence and pregnancy outcomes of intrahepatic cholestasis of pregnancy: A retrospective clinical audit review. Obstet Med 2019; 12: 123–128. doi:10.1177/1753495x18797749
[7] Smith DD, Rood KM. Intrahepatic Cholestasis of Pregnancy. Clin Obstet Gynecol 2020; 63: 134–151. doi:10.1007/1096-8278-004509
[8] Wikström Shemer E, Marschall HU, Ludvigsson JF et al. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG 2013; 120: 717–723. doi:10.1111/1471-0528.12174
[9] Rissanen AS, Jemman RM, Gissler M et al. Maternal complications in twin pregnancies in Finland during 1987–2014: a retrospective study. BMC Pregnancy Childbirth 2019; 19: 337. doi:10.1186/s12884-019-2498-x
[10] Ropponen A, Sund R, Rikonen S et al. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology 2006; 43: 723–728. doi:10.1002/hep.21111
[11] Turunen K, Molsa A, Helander K et al. Health history after intrahepatic cholestasis of pregnancy. Acta Obstet Gynecol Scand 2012; 91: 679–685. doi:10.1111/j.1600-0412.2012.01403.x
[12] Lammert F, Marschall HU, Matern S. Intrahepatic Cholestasis of Pregnancy. Curr Treat Options Gastroenterol 2003; 6: 123–132. doi:10.1007/s11938-003-0013-x
[13] Dixon PH, Williamson C. The pathophysiology of intrahepatic cholestasis of pregnancy. Clin Res Hepatol Gastroenterol 2016; 40: 141–153. doi:10.1016/j.clinre.2015.12.008
[14] Pecks U, Mohaupt MG, Hüttner MC et al. Cholesterol acceptor capacity is preserved by different mechanisms in preterm and term fetuses. Biochim Biophys Acta 2014; 1841: 251–258. doi:10.1016/j.bbabip.2013.11.008
[15] Zollner G, Marschall HU, Wagner M et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 2006; 3: 231–251. doi:10.1021/mp060010s
[16] Di Guida F, Pirozzi C, Magliocca S et al. Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis. Mol Pharm 2018; 15: 21–30. doi:10.1021/acs.molpharmaceut.7b00626
[17] Dixon PH, Weerasekera N, Linton KJ et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000; 9: 1299–1321. doi:10.1093/hmg/9.8.129
[18] Gendrot C, Bacq Y, Brechot MC et al. A second heterozygous MDR3 non-sense mutation associated with intrahepatic cholestasis of pregnancy. J Med Genet 2003; 40: e32. doi:10.1136/jmg.40.3.e32
[19] Floreani A, Corderi I, Paternoster D et al. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment Pharmacol Ther 2006; 23: 1649–1653. doi:10.1111/j.1365-2036.2006.02869.x
[20] Painter JN, Savander M, Ropponen A et al. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur J Hum Genet 2005; 13: 435–439. doi:10.1038/sj.ejhg.5201355
[21] Abu-Hayeh S, Ovadia C, Lieu T et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and nulliparous gravidarum. Hepatology 2016; 63: 1287–1298. doi:10.1002/hep.28265
[22] Pecks U, Rath W, Kleine-Eggebrecht N et al. Maternal Serum Lipid, Estradiol, and Progesterone Levels in Pregnancy, and the Impact of Placental and Hepatic Pathologies. Geburtsh Frauenheilk 2016; 76: 799–808. doi:10.1055/s-0042-107078
[23] Aleksunes LM, Yeager RL, Wen X et al. Repression of hepatobiliary transporters and differential regulation of classic and alternative bile acid pathways in mice during pregnancy. Toxicol Sci 2012; 130: 257–268. doi:10.1093/toxsci/kfs248
[24] Padda MS, Sanchez M, Akhtar AJ et al. Drug-induced cholestasis. Hepatology 2011; 53: 1377–1387. doi:10.1002/hep.24229
[25] Geier A, Wagner M, Dietrich CG et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007; 1773: 283–307. doi:10.1016/j.bbalip.2007.02.008
[26] Tribe RM, Dann AT, Kenyon AP et al. Longitudinal profiles of 15 serum bile acids in patients with intrahepatic cholestasis of pregnancy. Am J Gastroenterol 2010; 105: 585–595. doi:10.1038/aaj.2009.633
[27] Corellk J, Shevchuk A, de Swiet M et al. Comparison of the arrhythmogenic effects of tauro- and glycoconjugates of cholic acid in an in vitro study of rat cardiomyocytes. BJOG 2004; 111: 867–870. doi:10.1111/j.1471-0528.2004.00166.x
[28] Wijampreecsa K, Thongprayoon C, Sanguankee A et al. Hepatitis C infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017; 41: 39–45. doi:10.1016/j.clinre.2016.07.004
[29] Jiang R, Wang T, Yao Y et al. Hepatitis B infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis. Medicine (Baltimore) 2020; 99: e21416. doi:10.1097/MD.00000000000021416
[30] Marschall HU, Wikström Shemer E, Ludvigsson JF et al. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. Hepatology 2013; 58: 1385–1391
[31] Gonzalez MC, Reyes H, Arrese M et al. Intrahepatic cholestasis of pregnancy in twin pregnancies. J Hepatol 1989; 9: 84–90. doi:10.1016/0168-8278(89)00079-2
Mutlu MF, Aslan K, Guler I et al. Two cases of first onset intrahepatic cholestasis of pregnancy associated with moderate ovarian hyperstimulation syndrome after IVF treatment and review of the literature. J Obstet Gynaecol 2017; 37: 547–549. doi:10.1080/01443635.2017.1286302

Wanggren K, Sparre LS, Wramby H. Severe jaundice in early IVF pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 112: 228–229. doi:10.1016/j.ejogrb.2003.06.039

Geenes V, Chappell LC, Seed PT et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014; 59: 1482–1491. doi:10.1002/hep.26617

Liu X, Landon MB, Chen Y et al. Perinatal outcomes with intrahepatic cholestasis of pregnancy in twin pregnancies. J Matern Fetal Neonatal Med 2016; 29: 2176–2181. doi:10.3109/14767058.2015.1079612

Zizpan Y, Bachar G, Farago N et al. Vaginal progesterone treatment for the prevention of preterm birth and intrahepatic cholestasis of pregnancy: A case-control study. Eur J Obstet Gynecol Reprod Biol 2020; 253: 117–120. doi:10.1016/j.ejogrb.2020.08.043

Jie Z, Yiling D, Ling Y. Association of assisted reproductive technology with adverse pregnancy outcomes. Iran J Reprod Med 2015; 13: 169

Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009; 15: 2049–2066. doi:10.3748/wjg.v15.i24.2049

Floreani A, Gervasi MT. New Insights on Intrahepatic Cholestasis of Pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 112: 228–229. doi:10.1016/s0301-2115(03)00339-7

Droge C, Haussinger D, Keitel V. Genetic variants in adult liver diseases. Z Gastroenterol 2016; 29: 2176–2181. doi:10.1055/s-0042-118388

Keitel V, Droge C, Stepanow S et al. Intrahepatic cholestasis of pregnancy and its complications. Analysis of 100 cases in Chongqing area. Chin Med J (Engl) 1986; 99: 957–960

van den Berg B, Helm G, Petersohn L et al. Cholestasis of pregnancy: clinical and laboratory studies. Acta Obstet Gynecol Scand 1986; 65: 107–113

Lammert F, Marschall HU, Clanzet A et al. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 2000; 33: 1012–1021. doi:10.1016/S0168-8278(00)08139-7

Kremer AE, Bolier R, Dixon PH et al. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J Hepatol 2015; 62: 897–904. doi:10.1016/j.jhep.2014.10.041

Ghent CN, Bloomer JR, Katskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology 1977; 73: 1125–1130

Arafa A, Dong YJ. Association between intrahepatic cholestasis of pregnancy and risk of gestational diabetes and preeclampsia: a systematic review and meta-analysis. Hypertens Pregnancy 2020; 39: 354–360. doi:10.1080/10641955.2020.1758939

Majewska A, Godek B, Bomba-Opon D et al. Association between intrahepatic cholestasis in pregnancy and gestational diabetes mellitus. A retrospective analysis. Ginekol Pol 2019; 90: 458–463. doi:10.5603/GP.2019.0079

Martineau M, Raker C, Powrie R et al. Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. Eur J Obstet Gynecol Reprod Biol 2014; 176: 80–85. doi:10.1016/j.ejogrb.2013.12.037

Rav Y, Lavie A, Vered Y et al. Severe intrahepatic cholestasis of pregnancy is a risk factor for preeclampsia in singleton and twin pregnancies. Am J Obstet Gynecol 2015; 213: 395.e1–395.e8. doi:10.1016/j.ajo.2015.05.011

Vanjak D, Moreau R, Roche-Sicot J et al. Intrahepatic cholestasis of pregnancy and acute fatty liver of pregnancy. An unusual but favorable association? Gastroenterology 1991; 100: 1123–1125. doi:10.1016/0016-5085(91)90292-s

Jiang ZH, Qiu ZD, Liu WW et al. Intrahepatic cholestasis of pregnancy and its complications. Analysis of 100 cases in Chongqing area. Chin Med J (Engl) 1986; 99: 957–960

Kenyon AP, Piercy CN, Girling J et al. Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG 2002; 109: 282–288

AP Kenyon, Girling JC, Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis (Green-top Guideline No. 43). 2011. Accessed December 14, 2020 at: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg43/

Maldonado M, Alhoussine A, Awadalla M et al. Intrahepatic Cholestasis of Pregnancy Leading to Severe Vitamin K Deficiency and Coagulopathy. Case Rep Obstet Gynecol 2017; 2017: 5646247. doi:10.1155/2017/5646247

Furrer R, Winter K, Schäffer L et al. Postpartum blood loss in women treated for intrahepatic cholestasis of pregnancy. Obstet Gynecol 2016; 128: 1048–1052

Biberoglu EH, Kirbas A, Kirbas O et al. Prediction of cardiovascular risk by electrocardiographic changes in women with intrahepatic cholestasis of pregnancy. J Matern Fetal Neonatal Med 2015; 28: 2239–2243

Rainer PF, Primessing U, Harenkamp S et al. Bile acids induce arrhythmias in human atrial myocardium–implications for altered serum bile acid composition in patients with atrial fibrillation. Heart 2013; 99: 1685–1692

Desai MS, Penny DJ. Bile acids induce arrhythmias: old metabolite, new tricks. Heart 2013; 99: 1629–1630. doi:10.1016/j.heart.2013-304546

Vasavan T, Ferraro E, Ibrahim E et al. Heart and bile acids – Clinical consequences of altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis 2018; 1864 (4 Pt B): 1345–1355. doi:10.1016/j.bbadis.2017.12.039

Keitel V, Droge C, Stepanow S et al. Intrahepatic cholestasis of pregnancy (ICP): case report and review of the literature. Z Gastroenterol 2016; 54: 1327–1333. doi:10.1055/s-0042-118388

Shemer EAW, Stephansson O, Thoresen M et al. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. J Hepatol 2015; 63: 456–461

Geenes V, Lovgren-Sandblom A, Benthin L et al. The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. PLoS One 2014; 9: e83828. doi:10.1371/journal.pone.0083828

Blencowe H, Cousens S, Jassir FB et al. National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. Lancet Glob Health 2016; 4: e98–e108

Ovadia C, Seed PT, Sklavounos A et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019; 393: 899–909. doi:10.1016/S0140-6736(18)31877-4

Williamson C, Corellik J, Eaton BM et al. The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. Clin Sci (Lond) 2001; 100: 363–369
Fisk NM, Bye WB, Storey GN. Maternal features of obstetric cholestasis: 20 years experience at King George V Hospital. Aust N Z J Obstet Gynaecol 1988; 28: 172–176. doi:10.1111/j.1479-828x.1988.tb01657.x

Heikkinen J. Serum bile acids in the early diagnosis of intrahepatic cholestasis of pregnancy. Obstet Gynecol 1983; 61: 581–587

Laatikainen T, Ikonen E. Serum bile acids in cholestasis of pregnancy. Obstet Gynecol 1977; 50: 313–318

Milikiewicz P, Gallagher R, Chambers J et al. Obstetric cholestasis with elevated gamma glutamyl transpeptidase: incidence, presentation and treatment. J Gastroenterol Hepatol 2003; 18: 1283–1286. doi:10.1046/j.1440-1746.2003.03171.x

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237–267

Lammert F. Leber und Schwangerschaft. In: Tannapfel A, Klöppel G, Hrsg. Pathologie: Leber, Gallenwege und Pankreas. Berlin, Heidelberg: Springer; 2020: 429–436. doi:10.1007/978-3-642-04557-8_12

Rath W, Tsikouras P, Stelb P. HELLP Syndrome or Acute Fatty Liver of Pregnancy: A Differential Diagnostic Challenge: Common Features and Differences. Geburtshilfe Frauenheilkd 2020; 80: 499–507. doi:10.1055/a-1091-8630

Herold G. Innere Medizin-Ausgabe 2013. In: Herold G, Hrsg. Köln: 2014: 514–539

Kainer F. Facharztwissen Geburtshaus. 3. Aufl. Jena: Urban & Fischer Verlag/Elsevier GmbH; 2016

Lee RH, Greenberg M, Metz TD et al. Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: replaces Consult #13, April 2011. Am J Obstet Gynecol 2021; 224: B2–B9. doi:10.1016/j.ajog.2020.11.002

Toprak V, Kafadar MT. Intrahepatic cholestasis of pregnancy: is fetoplacental doppler ultrasound useful in the diagnosis and follow-up? Ann Clin Lab Anal 2020. doi:10.4328/ACAM.20203

Joutsiniemi T, Timonen S, Leino R et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Arch Gynecol Obstet 2014; 289: 541–547. doi:10.1007/s00404-013-2995-5

Zhang L, Liu XH, Qi HB et al. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. Eur Rev Med Pharmacol Sci 2015; 19: 3770–3776

Fleminger J, Seed PT, Smith A et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a secondary analysis of the PITCHES trial. BJOG 2020. doi:10.1111/1471-0528.16567

Haslinger C. The problem of uncertain adherence to study interventions: what can we conclude? BJOG. 2020. doi:10.1111/1471-0528.16613

Borges Mann A, Papacleovoulou G, Flaviani F et al. Ursodeoxycholic acid improves feto-placental and offspring metabolic outcomes in hypercholameric pregnancy. Sci Rep 2020; 10: 10361. doi:10.1038/s41598-020-67301-1

Fachinformation. Ursofalk® 250 mg Kapseln. 2018. Accessed December 14, 2020 at: https://www.fachinfo.de/pdf/002220

Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy 2012; 379271. doi:10.1155/2012/379271

Marschall HU, Wagner M, Zoller G et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476–485. doi:10.1016/j.gastro.2005.05.009

Liu J, Murray AM, Mankus EB et al. Adjuvant Use of Rifampin for Refractory Intrahepatic Cholestasis of Pregnancy. Obstet Gynecol 2018; 132: 678–681. doi:10.1097/AOG.0000000000002794

Geenes V, Chambers J, Khurana R et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. Eur J Obstet Gynecol Reprod Biol 2015; 189: 59–63. doi:10.1016/j.ejogrb.2015.03.020

Hague WM, Callaway L, Chambers J et al. A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of Ursodeoxycholic acid with Rifampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial. BMC Pregnancy Childbirth 2021; 21: S1. doi:10.1186/s12884-020-03481-y

Sadler LC, Lane M, North R. Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 1995; 102: 169–170. doi:10.1111/j.1471-0528.1995.tb09077.x

Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005; 129: 894–901. doi:10.1053/j.gastro.2005.06.019

Boelsterli UA, Rahit G, Balazs T. Modulation by S-adenosyl-L-methionine of hepatic Na+,K+-ATPase, membrane fluidity, and bile flow in rats with ethynyl estradiol-induced cholestasis. Hepatology 1983; 3: 12–17. doi:10.1002/hep.1840030102

Cantoni G. The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate 1, 2. J Am Chem Soc 1952; 74: 2942–2943

Stramentinoli G, Di Padova C, Gualano M et al. Ethynylestradiol-induced impairment of bile secretion in the rat: protective effects of S-adenosyl-L-methionine and its implication in estrogen metabolism. Gastroenterology 1981; 80: 154–158

Roncaglia N, Locatelli A, Arregnhi A et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG 2004; 111: 17–21. doi:10.1046/j.1471-0528.2003.00029.x
Triunfo S, Tomaselli M, Ferraro MI et al. Does mild intrahepatic cholestasis of pregnancy require an aggressive management? Evidence from a prospective observational study focused on adverse perinatal outcomes and pathological placental findings. J Matern Fetal Neonatal Med 2020. doi:10.1080/14767058.2020.1714583

Nicastri PL, Diaferia A, Tartagni M et al. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 1998; 105: 1205–1207. doi:10.1111/j.1471-0528.1998.tb09976.x

Hirvioja ML, Tuimala R, Vuori J. The treatment of intrahepatic cholestasis of pregnancy by dexamethasone. Br J Obstet Gynaecol 1992; 99: 109–111. doi:10.1111/j.1471-0528.1992.tb14465.x

Diac M, Kenyon A, Nelson-Piercy C et al. Dexamethasone in the treatment of obstetric cholestasis: a case series. J Obstet Gynaecol 2006; 26: 110–114. doi:10.1080/0144361050043246

Kretowicz E, McIntyre HD. Intrahepatic cholestasis of pregnancy, worsening after dexamethasone. Aust N Z J Obstet Gynaecol 1994; 34: 211–213. doi:10.1111/j.1479-828x.1994.tb02695.x

Melamed N, Asztalos E, Murphy K et al. Neurodevelopmental disorders among term infants exposed to antenatal corticosteroids during pregnancy: a population-based study. BMJ Open 2019; 9: e031197. doi:10.1136/bmjopen-2019-031197

embryotox.de. Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie. 2020. Accessed December 14, 2020 at: https://www.embryotox.de/arzneimittel

Kremer AE, van Dijk R, Leckie P et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012; 56: 1391–1400. doi:10.1002/hep.25748

Henderson CE, Shah RR, Gottimukkala S et al. Primum non nocere: how active management became modus operandi for intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol 2014; 211: 189–196

Cheng YW, Kaimal AJ, Bruckner TA et al. Perinatal morbidity associated with late preterm deliveries compared with deliveries between 37 and 40 weeks of gestation. BJOG 2011; 118: 1446–1454

Kehl S, Abou-Dakn M, Hösi I et al. Induction of labour. Guideline of the German Society of Gynecology and Obstetrics (S2k, AWMF Registry No. 015–088, December 2020). 2020. Accessed December 22, 2020 at: https://www.awmf.org/uploads/tx_szleitlinien/015-088ladd_S2k_Geburteinleitung_2021-04.pdf

Wikstrom Shemer EA, Thorsell M, Marschall HU et al. Risks of emergency cesarean section and fetal asphyxia after induction of labor in intrahepatic cholestasis of pregnancy: a hospital-based retrospective cohort study. Sex Reprod Healthc 2013; 4: 17–22. doi:10.1016/j.srhc.2012.11.005

Webster JR, Chappell L, Cheng F et al. Operative delivery rates following induction of labour for obstetric cholestasis. Obstet Med 2011; 4: 66–69. doi:10.1258/om.2011.110080

Curtis KM, Tepper NK, Jatlaoui TC et al. US medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016; 65; 1–103

Guðbjartsson DF, Helgason H, Guðjónsson SA et al. Large-scale whole-genome sequencing of the Icelandic population. Nat Genet 2015; 47: 435–444. doi:10.1038/ng.3247